Elsevier

Virology

Volume 353, Issue 2, 30 September 2006, Pages 324-332
Virology

Complex adenovirus-vectored vaccine protects guinea pigs from three strains of Marburg virus challenges

https://doi.org/10.1016/j.virol.2006.05.033Get rights and content
Under an Elsevier user license
open archive

Abstract

The Marburg virus (MARV), an African filovirus closely related to the Ebola virus, causes a deadly hemorrhagic fever in humans, with up to 90% mortality. Currently, treatment of disease is only supportive, and no vaccines are available to prevent spread of MARV infections. In order to address this need, we have developed and characterized a novel recombinant vaccine that utilizes a single complex adenovirus-vectored vaccine (cAdVax) to overexpress a MARV glycoprotein (GP) fusion protein derived from the Musoke and Ci67 strains of MARV. Vaccination with the cAdVaxM(fus) vaccine led to efficient production of MARV-specific antibodies in both mice and guinea pigs. Significantly, guinea pigs vaccinated with at least 5 × 107 pfu of cAdVaxM(fus) vaccine were 100% protected against lethal challenges by the Musoke, Ci67 and Ravn strains of MARV, making it a vaccine with trivalent protective efficacy. Therefore, the cAdVaxM(fus) vaccine serves as a promising vaccine candidate to prevent and contain multi-strain infections by MARV.

Keywords

Marburg virus
Vaccine
cAdVax
Glycoprotein
Challenge
Musoke
Ravn
Ci67

Cited by (0)